Helicobacter最新文献

{"title":"Vonoprazan Versus Tegoprazan–Amoxicillin Dual Therapy for Treatment-Naïve Patients With Helicobacter pylori Infection: A Prospective, Multicenter, Open-Label, Randomized Controlled Study","authors":"Ya-Ni Zhou, Ji-Chun Song, Qing-Hua Wang, Huang Feng, Ya Lin, De-Min Li, Ge Wang, Xiao-Wei Huang, Jing-Mei Liu, Yan Shen, Xiang Zhou, Hui-Ting Xue, Yan Liu, Pei-Yuan Li","doi":"10.1111/hel.70124","DOIUrl":"10.1111/hel.70124","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>High-dose dual therapy (HDDT) has been shown to achieve eradication rates non-inferior to the bismuth quadruple therapy (BQT) in treatment-naïve patients of <i>Helicobacter pylori (H. pylori)</i> infection, with advantages including greater convenience and fewer adverse events. However, the efficacy of different potassium-competitive acid blockers (P-CABs) in HDDT regimens remains incompletely defined due to variations in their pharmacokinetic properties. Therefore, this study aims to evaluate the eradication rates, incidence of adverse events, and compliance of the dual regimens of vonoprazan/tegoprazan combined with amoxicillin in patients with treatment-naïve <i>H. pylori</i> infection.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>This prospective, multicenter, open-label, randomized controlled clinical trial enrolled newly diagnosed patients with H. pylori infection from six centers in China. All subjects were randomly assigned to the VA group (vonoprazan 20 mg bid+amoxicillin 1 g tid, 14 days) or the TA group (tegoprazan 50 mg bid+amoxicillin 1 g tid, 14 days). The basic information and clinical data of the patients were collected via electronic questionnaires, WeChat, or telephone follow-ups. H. pylori eradication was assessed 4 weeks post-treatment using the urea breath test (UBT). The adverse events and compliance were meticulously recorded throughout the treatment period.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Result</h3>\u0000 \u0000 <p>Between June 2024 and May 2025, 710 patients were randomly assigned, and 653 subjects were included. In the intention-to-treat (ITT) analysis, the eradication rates were 89.3% in the VA group and 76.1% in the TA group, respectively (<i>p</i> < 0.001). The modified intention-to-treat (mITT) analysis showed rates of 94.6% and 80.8%, respectively (<i>p</i> < 0.001), and the per-protocol (PP) analysis yielded 95.1% and 81.0%, respectively (<i>p</i> < 0.001). Although the overall incidence of adverse event rates was comparable between groups (17.2% vs. 13.8%, <i>p</i> = 0.254), gastrointestinal adverse events were less frequent with TA therapy (9.3% vs. 14.4%, <i>p</i> = 0.048). Compliance was excellent and comparable in both groups (94.6% vs. 94.1%, respectively, <i>p</i> = 0.871). None of the factors analyzed significantly influenced eradication rates.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Vonoprazan/amoxicillin dual therapy achieved satisfactory <i>H. pylori</i> eradication rates with a favorable safety profile in treatment-naïve patients. Tegoprazan/amoxicillin dual therapy was associated with fewer gastrointestinal adverse event incidences, while opti","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"31 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147592032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Helicobacter 30 Years On: A Message From the Editor, Emeritus","authors":"David Y. Graham","doi":"10.1111/hel.70118","DOIUrl":"10.1111/hel.70118","url":null,"abstract":"","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"31 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147592017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Association of a Positive Fecal Immunochemical Test With the Risk of Gastroesophageal Cancer: An Age-Sex-H. Pylori Exposure Matched Cohort Study and Cost-Effectiveness Analysis","authors":"Zohar Levi,&nbsp;Naim Abu-Freha,&nbsp;Doron Boltin,&nbsp;Maya Aharoni Golan,&nbsp;Tom Konikoff,&nbsp;Orly Sneh Arbib,&nbsp;Rachel Gingold Belfer,&nbsp;Sapir Eizenstein,&nbsp;Alex Vilkin,&nbsp;Shiri Kusnir,&nbsp;Adi Turgeman,&nbsp;Tanya Babich,&nbsp;Moshe Leshno,&nbsp;Anath A. Flugelman,&nbsp;Hadar Edelman-Klapper,&nbsp;Elizabeth Half-Onn","doi":"10.1111/hel.70120","DOIUrl":"10.1111/hel.70120","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>We evaluated the association between Fecal Immunochemical Test (FIT) results and the risk of gastroesophageal cancer (GEC) in a matched cohort, as well as the cost-effectiveness of a one-time esophagogastroduodenoscopy (EGD) for individuals who tested FIT-positive.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We formed a cohort of individuals aged 50–75 years who underwent FIT testing at Clalit Health in Israel from 2016 to 2019. For each person with a positive FIT result, we matched three individuals with negative results by age, gender, and <i>H. pylori</i> exposure. We used adjusted hazard ratios (adjHRs) to assess the association between a positive FIT result and the risk of GEC within 36 months. We calculated the incremental cost-effectiveness ratio (ICER) for a one-time EGD costing USD 350 in individuals who tested positive for FIT, and considered it cost-effective if below USD 50,000.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The study included 150,391 individuals (47.6% female, median age 62.4 years). During follow-up, 202 cases of GEC were recorded: 0.17% in FIT-positive individuals (64/37,709) and 0.12% in FIT-negative individuals (138/112,682), adjHR 1.39 (95% CI 1.03–1.87). GEC was also associated with <i>H. pylori</i> exposure (adjHR 1.43, 95% CI 1.08–1.90) and immigration from high-risk countries. A one-time EGD demonstrated favorable cost-effectiveness across various scenarios, with an ICER of USD 25,535/QALY.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This matched-cohort study suggests that individuals with a positive FIT may have an increased risk of GEC, comparable to that of established high-risk populations. Adding a one-time EGD to colonoscopy for FIT-positive individuals may be a cost-effective approach for healthcare systems that can accommodate such interventions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"31 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13009314/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147503811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Helicobacter pylori, Inflammation, and Long-Term Outcome in Patients With Acute Myocardial Infarction: A Prospective Cohort Study","authors":"Martin O. Sundqvist,&nbsp;Jonatan Wärme,&nbsp;Marcus Hjort,&nbsp;Per Tornvall,&nbsp;Tomas Jernberg,&nbsp;Bertil Lindahl,&nbsp;Alexandru Schiopu,&nbsp;Tomasz Baron,&nbsp;Stefan H. Jacobson,&nbsp;Thomas Kahan,&nbsp;David Erlinge,&nbsp;Jonas Spaak,&nbsp;Robin Hofmann","doi":"10.1111/hel.70116","DOIUrl":"10.1111/hel.70116","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p><i>Helicobacter pylori</i> (Hp) and its virulence factor Cytotoxin-associated gene A (CagA) have been linked to myocardial infarction (MI), but the mechanisms are unknown. This study aims to test if Hp infection and CagA are associated with pre-specified inflammatory and vascular biomarkers in patients with MI and to explore whether a broader biomarker panel can predict infection. Furthermore, it aims to investigate the association of Hp infection and biomarkers with major adverse cardiovascular events (MACE) and mortality.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Hp, CagA serology, and 175 cardiovascular biomarkers were analyzed in 1061 patients with MI admitted between 2008 and 2014. Associations between Hp and seven pre-selected biomarkers were evaluated. Exploratory analyses included all biomarkers using machine-learning models to predict Hp-status. Hp-status and the top predictors were analyzed for associations with outcomes using Cox regression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Median age was 65 years; 78% were male. Hp and CagA seroprevalence were 45% and 19%, respectively. Patients with Hp had elevated CRP (<i>β</i> = 0.26, 95% CI 0.01–0.51). Predictive performance of Hp-status was moderate (AUC 0.63–0.68). Exploratory analysis identified higher levels of C-C motif chemokine ligand 20 (CCL20) and immunoglobulin heavy constant gamma-3 (IGHG3), and lower levels of TNF-related apoptosis-inducing ligand (TRAIL) in patients with Hp-positivity. Elevated CCL20 and reduced TRAIL, but not Hp, were associated with MACE and all-cause mortality.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Hp may contribute to an inflammatory response in patients with MI, indicated by higher CRP and inflammatory/immune-modulatory biomarkers emerging as its top predictors. Although Hp was not associated with adverse outcomes after MI, its predictive inflammatory biomarkers were associated with MACE and mortality.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>The study was not registered as a clinical trial, as it was an observational study</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"31 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12989639/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147463401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes of Helicobacter pylori Infection Status and Risk of Precancerous Lesions: A Prospective Cohort Study in Chinese Population","authors":"Xufei Xing,&nbsp;Renjia Zhao,&nbsp;Zixuan Cui,&nbsp;Qiaoyi Xu,&nbsp;Ziyu Yuan,&nbsp;Kelin Xu,&nbsp;Tiejun Zhang,&nbsp;Zhenqiu Liu,&nbsp;Yanfeng Jiang,&nbsp;Ming Lu,&nbsp;Weimin Ye,&nbsp;Chen Suo,&nbsp;Xingdong Chen","doi":"10.1111/hel.70114","DOIUrl":"10.1111/hel.70114","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To evaluate the associations of both baseline serological profiles and serological transitions of <i>Helicobacter pylori</i> infection patterns with the risk of precancerous gastric lesions (PGLs).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Design</h3>\u0000 \u0000 <p>We analyzed data from 6208 participants in the FuSion cohort who underwent gastroscopy examination, with available <i>H. pylori</i> antibody and pepsinogen measurements at both baseline and follow-up. <i>H. pylori</i> status defined by IgG antibodies (Ab) and pepsinogens (PG), classified participants into four ABC groups. Multivariable logistic regression evaluated associations with PGLs across baseline and transition statuses. Trend tests were performed across the ABC groups and infection transition categories.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A significant increasing trend in the PGLs prevalence and severity was observed across the ABC groups (<i>p</i> for trend &lt; 0.05). Analysis of infection transitions revealed graded risk increases for PGLs from consistently negative to remained positive groups. Interestingly, even participants who seroreverted remained at significantly elevated risks of atrophic gastritis (adjusted odds ratio [aOR] = 2.01, 95% CI: 1.67–2.43) and intestinal metaplasia (aOR = 1.72, 95% CI: 1.14–2.51) compared to the persistently negative participants. The sensitivity analyses excluding baseline PG-positive subjects yielded similar results.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Long-term exposure to <i>H. pylori</i> is associated with an increased risk of PGLs, and this risk may remain elevated even after seroreversion.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"31 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147364877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing Benefits-Harms of H. pylori Screen-and-Treat Programs Tailored to the Regional Settings","authors":"Duco T. Mülder,&nbsp;Yi-Chia Lee,&nbsp;Mario Dinis-Ribeiro,&nbsp;Melissa McLeod,&nbsp;Jin Young Park,&nbsp;Iris Lansdorp-Vogelaar","doi":"10.1111/hel.70111","DOIUrl":"10.1111/hel.70111","url":null,"abstract":"<p>This article outlines how decision modeling can be used to optimize the cost-effectiveness of <i>H. pylori</i> screen-and-treat programs. Decision models enable the translation of data from pilot studies into locally tailored strategies by adapting test modalities, treatment options, and the need to retest specific to the local setting. We summarize existing evidence from modeling studies, which consistently demonstrate that <i>H. pylori</i> screen-and-treat is cost-effective across diverse populations. In addition, we discuss how decision modeling can support resource allocation, promote health equity, and guide implementation planning. Integrating <i>H. pylori</i> screen-and-treat into established preventive programs, such as colorectal cancer screening, may further increase efficiency and feasibility. The article concludes with a proposed research agenda to advance efficient <i>H. pylori</i> screen-and-treat programs across the globe.</p>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"31 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12960071/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147354833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Vonoprazan-Based Dual, Triple, and Quadruple Therapies for Helicobacter pylori Eradication: A Randomized Controlled Trial","authors":"Jin-Yan Zhang,&nbsp;Ji Li,&nbsp;Wei-Feng Huang,&nbsp;Xiao-Yi Lei,&nbsp;Yu-Lin Huang,&nbsp;Gui-Hua Xu,&nbsp;Dong Xu","doi":"10.1111/hel.70112","DOIUrl":"10.1111/hel.70112","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Vonoprazan (VPZ), a potassium-competitive acid blocker, has shown promising efficacy in <i>Helicobacter pylori</i> (<i>H. pylori</i>) eradication. However, direct comparisons of VPZ-based dual therapy (V-DT), triple therapy (V-TT), and bismuth quadruple therapy (V-BQT) remain limited. This study aimed to evaluate and compare the efficacy, safety, and compliance of these three regimens as first-line treatments for <i>H. pylori</i> infection.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>375 adults were randomized (1:1:1) to receive V-DT (VPZ 20 mg bid + amoxicillin 1 g tid for 10 days), V-TT (VPZ 20 mg bid + amoxicillin 1 g bid + clarithromycin 500 mg bid for 14 days), or V-BQT (VPZ 20 mg bid + amoxicillin 1 g bid + clarithromycin 500 mg bid + bismuth 240 mg bid for 10 days). The primary outcome was <i>H. pylori</i> eradication rate by intention-to-treat (ITT), modified ITT (mITT), and per-protocol (PP) analyses. Secondary outcomes included adverse events and compliance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Eradication rates were 92.0% (95% confidence interval [CI]: 85.8%–96.1%), 89.6% (95% CI: 82.9%–94.3%), and 88.8% (95% CI: 81.9%–93.7%) in ITT; 94.3% (95% CI: 88.5%–97.7%), 94.9% (95% CI: 89.3%–98.1%), and 94.1% (95% CI: 88.2%–97.6%) in mITT; and 94.2% (95% CI: 88.4%–97.6%), 95.6% (95% CI: 90.0%–98.5%), and 94.8% (95% CI: 89.0%–98.1%) in PP analyses for V-DT, V-TT, and V-BQT, respectively. The efficacy of V-DT and V-TT was noninferior to that of V-BQT. Adverse events were significantly lower with V-DT (6.4%) than with V-TT (36.0%) and V-BQT (49.6%) (<i>p</i> &lt; 0.001). Compliance exceeded 93% in all groups, with no significant differences (<i>p</i> = 0.250).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>All three regimens achieved high eradication rates, with V-DT and V-TT being statistically noninferior to V-BQT. The 10-day V-DT regimen achieved eradication rates comparable to V-BQT with substantially fewer adverse events and reduced antibiotic use, supporting its potential as a simplified first-line option for <i>H. pylori</i> eradication.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>Chinese Clinical Trial Registration Number: ChiCTR2300072857</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"31 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147354848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exosome-Based Detection of Helicobacter pylori Infection and Clarithromycin Resistance in Children","authors":"Minghui Song,&nbsp;Jingqing Zeng,&nbsp;Zhanyong Yao,&nbsp;Chundi Xu,&nbsp;Yiqiu Huang,&nbsp;Yuan Xiao,&nbsp;Yi Yu,&nbsp;Jia Li,&nbsp;Xu Xu,&nbsp;Chenchen Shi,&nbsp;Qiuchen Wu,&nbsp;Yonglin Tao,&nbsp;Xing Tang,&nbsp;Gloria Ge,&nbsp;Shenshen Gao,&nbsp;Zhaohui Deng,&nbsp;Xinqiong Wang","doi":"10.1111/hel.70113","DOIUrl":"10.1111/hel.70113","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The prevalence of <i>Helicobacter pylori</i> (<i>H. pylori</i>) infection in children is high. Current diagnostic methods, particularly invasive techniques like gastroscopy, pose challenges for pediatric populations, highlighting the need for reliable non-invasive alternatives.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This study aimed to evaluate the diagnostic value of salivary and urinary exosomes for detecting <i>H. pylori</i> infection and clarithromycin resistance in children.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Saliva and urine samples were collected from children prior to elective gastroscopy. Exosomal DNA was extracted and subjected to qPCR for the detection of <i>H. pylori</i> DNA and clarithromycin resistance. The sensitivity and specificity of the salivary and urinary exosome tests were calculated against the reference standard, and their performance in detecting resistance was compared with tissue-based results.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 500 enrolled children, the <i>H. pylori</i> infection rate was 31.6%. Analysis of 500 salivary and 80 urine samples showed that salivary exosomes detected <i>H. pylori</i> with a sensitivity of 93.67% and specificity of 80.11%. Urinary exosomes offered higher specificity (90.56%) but lower sensitivity (62.96%). In the subset of 113 infected children tested for resistance, salivary exosome testing identified clarithromycin resistance in 17.70% of cases, showing a 91.15% concordance with gastric tissue testing (15.93%). The agreement between the two methods was substantial.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Salivary exosome-based detection represents a highly sensitive and well-tolerated non-invasive method for diagnosing <i>H. pylori</i> infection in children. It also demonstrates substantial agreement with invasive methods in identifying clarithromycin resistance, offering a promising tool to guide precise eradication therapy in the pediatric population.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"31 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147354868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Individuals and Family-Screen-to-Treat-Based Helicobacter pylori Eradication Strategy for Gastric Cancer Prevention: A Latin American Perspective.","authors":"José Darío Portillo-Miño, Javier Uribe, Gonzalo Latorre, Mauricio Pizarro, Margarita Pizarro, Nilton Palacios, Natalia Díaz-Garrido, Camila Jure, Diego Reyes-Placencia, William Otero, Sandra Cifuentes, Oscar Laudanno, José M Remes-Troche, Alejandro Piscoya, Arnoldo Riquelme","doi":"10.1111/hel.70110","DOIUrl":"10.1111/hel.70110","url":null,"abstract":"<p><p>Gastric cancer (GC) is a public health concern due to estimates indicating it ranks among the most prevalent cancers and leading causes of cancer-related deaths globally. In Latin America, a region significantly impacted by high mortality and incidence of GC, chronic H. pylori infection remains the primary cause of GC, with an overall prevalence of around 42.5% from 2015 to 2022. Asian countries have developed innovative strategies for primary and secondary prevention. Among the most notable primary and secondary screening programs were endoscopy-based screening in Japan and South Korea; a nationwide population-based H. pylori eradication program in Bhutan; mass H. pylori eradication in the Matsu Islands of Taiwan; and a recently developed family-based H. pylori eradication strategy in China. In this Opinion Review, we discuss the opportunities and pitfalls of implementing an individual-and family-screening-based H. pylori eradication strategy for GC prevention in Latin American intermediate- and high-risk areas.</p>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"31 2","pages":"e70110"},"PeriodicalIF":4.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147728700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hope Hp-GC Project-Program Implementation for Primary and Secondary Prevention of Gastric Cancer in Latin America.","authors":"Javier Uribe, José Darío Portillo-Miño, Gonzalo Latorre, Diego Reyes-Placencia, Mauricio Pizarro, José Ignacio Vargas, Alberto Espino, Camila Jure, Margarita Pizarro, Gabriela Bofill, Felipe Silva, Nilton Palacios, Natalia Díaz-Garrido, Laura Huidobro, Raúl Araya, Sergio Ledesma, William Otero, Lina Otero, José M Remes-Troche, Christian Campos, Monserrate Largacha, Oscar Varas, Dacio Cabrera, Alejandro Piscoya, Juan Ramírez, Oscar Laudanno, Sebastián Esteves, Sandra Cifuentes, Eduardo García, Ana María-Guzmán, Douglas Morgan, Manuel Espinoza, Shailja C Shah, Jin Young Park, M Constanza Camargo, Arnoldo Riquelme","doi":"10.1111/hel.70109","DOIUrl":"10.1111/hel.70109","url":null,"abstract":"<p><strong>Introduction: </strong>Gastric cancer (GC) is the fifth leading cause of cancer-related mortality globally; its main burden is concentrated in East Asia and some areas of Europe and Latin America. This study aims to develop an organized and structured GC prevention pilot program in intermediate-to-high-incidence countries in Latin America.</p><p><strong>Methods: </strong>This study involved two strategies: (a) primary prevention for screen-and-treat H. pylori infection among individuals aged 30-39 years (n = 7500, 500 in 15 sites), and (b) primary and secondary prevention for individuals aged 40-75 years (n = 9600, 600 in 16 sites) with tiered risk stratification using an algorithm developed and validated in Chile (Gastrocalc: priority 1 to 6; age, sex, hypertension, IgG H. pylori, pepsinogen I and II, and Gastrin-17b), and high-quality esophagogastroduodenoscopy (EGD) evaluation.</p><p><strong>Results: </strong>Pilot phases were successfully conducted in Chile and Colombia during 2023-2025. In Chile (Molina), 4152 asymptomatic individuals were tested with H. pylori prevalence of 46% (n = 113/246) in 2023, 34% (n = 504/1484) in 2024, and 32% (n = 609/1904) in 2025. The H. pylori prevalence among individuals aged 30-39 years (592/4152; 14.3%) was 37.8%. In Colombia, 1250 asymptomatic individuals were screened across four regions; in 2025, the prevalence of H. pylori among individuals aged 30-39 years was 69% (n = 895/1250). The validation of Gastrocalc included 866 individuals from 5 regions in Chile. The algorithm successfully identified 80.6% of OLGA III-IV patients and 100% of GC patients (Priority 1-4). Other countries will start activities in 2026.</p><p><strong>Conclusions: </strong>This pioneering study will advance understanding and feasibility of urgently needed primary and secondary prevention for GC in Latin America.</p>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"31 2","pages":"e70109"},"PeriodicalIF":4.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147722864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}